The entry of the Russian antiviral drug TRIAZAVIRIN® into the South African pharmaceutical market opens new opportunities not only for international healthcare cooperation but also for enhancing the health of patients in both countries.
South Africa remains one of the continent's largest pharmaceutical markets, where seasonal viral infections annually impose substantial pressure on the healthcare system. Growing interest in medications with proven efficacy and safety is driving the demand for innovative drugs for the prevention and treatment of influenza and acute respiratory viral infections.
TRIAZAVIRIN® is an original antiviral drug with the active ingredient (Riamilovir) that inhibits the replication of a wide range of RNA-containing viruses, including influenza, acute respiratory viral infections, COVID-19, and other related pathogens.